Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Allergy Therapeutics Vaccine Helps Dust Mite Allergy Symptoms In Study

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine ...

Alliance News 20 May, 2019 | 1:42PM
Email Form

LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said its Acarovac MPL vaccine improved dust mite allergy symptoms during a phase one study.

The AM101 study, which was open-label and intended to assess the safety and tolerability of the vaccine, involved 16 adult patients with house dust mite-mediated allergic rhinoconjunctivitis.

Allergy Therapeutics, a biotechnology company with a focus on allergy diagnosis and treatment, said the drug was well tolerated when administered as seven injections over 6 to 12 weeks each 1 to 2 weeks apart.

A secondary endpoint of the study included the vaccine's effect on patients' responses to nasal provocation test - a test in which the nose is exposed to the substance that causes the allergy.

In this case, a significant improvement from baseline was seen in patients' total symptom scores after a nasal provocation test after 12 weeks, with increased immunoglobulin markets and reduced IL-4 - a protein associated with allergies. Patients also reported high satisfaction with their treatment when given a questionnaire.

Allergy Therapeutics Chief Executive Manuel Llobet said: "The success of our clinical trial in house dust mite-induced allergic rhinitis is encouraging news for the many patients who continue to suffer with the symptoms caused by house dust mite allergy, and supports our ambition to provide a global therapy for the important US, China and EU markets.We believe Acarovac MPL could build on our success in dust mite immunotherapy and we look forward to progressing towards phase two clinical studies."

Shares in Allergy Therapeutics were down 0.8% at 12.40 pence on Monday afternoon.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Allergy Therapeutics PLC 12.95 GBX 3.60 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites